Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Etrolizumab was developed by Genentech [2] [3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. [4] As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab , it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection .
Genentech pioneered the use of recombinant human growth hormone for human therapy, which was approved by the FDA in 1985. [citation needed] Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Attempts to create a wholly synthetic HGH failed.
The first company to focus on genetic engineering, Genentech, was founded in 1976 and started the production of human proteins. Genetically engineered human insulin was produced in 1978 and insulin-producing bacteria were commercialised in 1982. Genetically modified food has been sold since 1994, with the release of the Flavr Savr tomato. The ...
Production of a single year's supply of human growth hormone required up to fifty pituitary glands, [3] creating significant shortages of the hormone. [4] In 1979, scientists at Genentech produced human growth hormone by inserting DNA coding for human growth hormone into a plasmid that was implanted in Escherichia coli bacteria.
5327 18791 Ensembl ENSG00000104368 ENSMUSG00000031538 UniProt P00750 P11214 RefSeq (mRNA) NM_033011 NM_000930 NM_000931 NM_001319189 NM_008872 RefSeq (protein) NP_000921 NP_001306118 NP_127509 NP_032898 Location (UCSC) Chr 8: 42.17 – 42.21 Mb Chr 8: 23.25 – 23.27 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Tissue-type plasminogen activator, short name tPA, is a protein that ...
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects. [5]